IL174591A0 - Composition and dosage form for sustained effect of levodopa - Google Patents
Composition and dosage form for sustained effect of levodopaInfo
- Publication number
- IL174591A0 IL174591A0 IL174591A IL17459106A IL174591A0 IL 174591 A0 IL174591 A0 IL 174591A0 IL 174591 A IL174591 A IL 174591A IL 17459106 A IL17459106 A IL 17459106A IL 174591 A0 IL174591 A0 IL 174591A0
- Authority
- IL
- Israel
- Prior art keywords
- levodopa
- composition
- dosage form
- sustained effect
- sustained
- Prior art date
Links
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title 1
- 239000002552 dosage form Substances 0.000 title 1
- 229960004502 levodopa Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000002459 sustained effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51297303P | 2003-10-20 | 2003-10-20 | |
| PCT/US2004/034121 WO2005042101A1 (en) | 2003-10-20 | 2004-10-14 | Composition and dosage form for sustained effect of levodopa |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL174591A0 true IL174591A0 (en) | 2006-08-20 |
Family
ID=34549241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL174591A IL174591A0 (en) | 2003-10-20 | 2006-03-27 | Composition and dosage form for sustained effect of levodopa |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20050113452A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1675651A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2007509146A (cg-RX-API-DMAC7.html) |
| KR (2) | KR20080109101A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004285436C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2553156A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA200600626A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL174591A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA06004327A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ546662A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005042101A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7674480B2 (en) | 2000-06-23 | 2010-03-09 | Teva Pharmaceutical Industries Ltd. | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
| DE10214188B4 (de) | 2002-03-28 | 2005-08-25 | Siemens Ag | Verfahren zur gesicherten Übertragung von Daten, insbesondere zur Übertragung über eine Luftschnittstelle |
| MX2007001058A (es) * | 2004-07-26 | 2007-04-16 | Teva Pharma | Formas de dosificacion con tableta nucleo recubierta entericamente. |
| US7780981B2 (en) | 2004-09-13 | 2010-08-24 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery |
| US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| US20070027216A1 (en) * | 2005-07-15 | 2007-02-01 | Bridget Larson | Novel hydrochloride salts of levodopa |
| EP1945188A2 (en) * | 2005-11-07 | 2008-07-23 | Teva Pharmaceutical Industries Ltd. | Levodopa compositions |
| UA95954C2 (ru) * | 2006-05-31 | 2011-09-26 | Солвей Фармасьютикалс Гмбх | Продолжительное 24-часовое введение в кишечник леводопа/карбидопа |
| US8765178B2 (en) | 2006-07-19 | 2014-07-01 | Watson Laboratories, Inc. | Controlled release formulations and associated methods |
| ES2521494T3 (es) * | 2007-04-02 | 2014-11-12 | Parkinson's Institute | Métodos y composiciones para la reducción de los efectos secundarios de tratamientos terapéuticos |
| EP2729148A4 (en) | 2011-07-06 | 2015-04-22 | Parkinson S Inst | COMPOSITIONS AND METHOD FOR THE TREATMENT OF SYMPTOMS IN PATIENTS WITH MORBUS PARKINSON |
| JP2018511355A (ja) | 2015-01-28 | 2018-04-26 | クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 薬剤送達方法及びシステム |
| US10679516B2 (en) | 2015-03-12 | 2020-06-09 | Morningside Venture Investments Limited | Craving input and support system |
| CA3049529A1 (en) | 2017-01-06 | 2018-07-12 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
| US11596779B2 (en) | 2018-05-29 | 2023-03-07 | Morningside Venture Investments Limited | Drug delivery methods and systems |
| CA3119992A1 (en) | 2018-11-16 | 2020-05-22 | Morningside Venture Investments Limited | Thermally regulated transdermal drug delivery system |
| IT202000019303A1 (it) * | 2020-08-05 | 2022-02-05 | Univ Degli Studi Di Brescia | Analoghi strutturali del metilfenidato come agenti disease-modifying della malattia di parkinson |
| EP4316482A1 (en) * | 2022-08-01 | 2024-02-07 | 4P-Pharma | Levodopa for preventing addiction |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3779500T2 (de) * | 1986-06-10 | 1993-01-21 | Chiesi Farma Spa | Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. |
| US4832957A (en) * | 1987-12-11 | 1989-05-23 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
| ZA889189B (en) * | 1986-06-16 | 1989-08-30 | Merck & Co Inc | Controlled release combination of carbidopa/levodopa |
| US4983400A (en) * | 1986-06-16 | 1991-01-08 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
| US4716246A (en) * | 1986-08-22 | 1987-12-29 | Merck & Co., Inc. | Process for L-dopa |
| US5994392A (en) * | 1988-02-26 | 1999-11-30 | Neuromedica, Inc. | Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid |
| US5041430A (en) * | 1989-09-18 | 1991-08-20 | Du Pont Mereck Pharmaceutical Company | Oral anticoagulant/platelet inhibitor low dose formulation |
| US5607969A (en) * | 1992-12-24 | 1997-03-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | L-DOPA ethyl ester to treat Parkinson's disease |
| US6117453A (en) * | 1995-04-14 | 2000-09-12 | Pharma Pass | Solid compositions containing polyethylene oxide and an active ingredient |
| US5840756A (en) * | 1995-07-21 | 1998-11-24 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition of L-DOPA ester |
| US6235311B1 (en) * | 1998-03-18 | 2001-05-22 | Bristol-Myers Squibb Company | Pharmaceutical composition containing a combination of a statin and aspirin and method |
| US6797283B1 (en) * | 1998-12-23 | 2004-09-28 | Alza Corporation | Gastric retention dosage form having multiple layers |
| US7674480B2 (en) * | 2000-06-23 | 2010-03-09 | Teva Pharmaceutical Industries Ltd. | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
| CA2412490A1 (en) * | 2000-06-23 | 2002-01-03 | Moshe Fleshner-Barak | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
| IL159715A0 (en) * | 2001-07-10 | 2004-06-20 | Teva Pharma | Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery |
| CN1620284B (zh) * | 2001-12-24 | 2010-04-28 | 特瓦制药工业有限公司 | 含有用粉末或粒状材料的压缩环状体包鞘的有效成分片芯的剂型,及其生产工艺和工具 |
| US20040052843A1 (en) * | 2001-12-24 | 2004-03-18 | Lerner E. Itzhak | Controlled release dosage forms |
-
2004
- 2004-10-14 CA CA002553156A patent/CA2553156A1/en not_active Abandoned
- 2004-10-14 EA EA200600626A patent/EA200600626A1/ru unknown
- 2004-10-14 JP JP2006536678A patent/JP2007509146A/ja active Pending
- 2004-10-14 KR KR1020087029777A patent/KR20080109101A/ko not_active Ceased
- 2004-10-14 MX MXPA06004327A patent/MXPA06004327A/es unknown
- 2004-10-14 US US10/966,090 patent/US20050113452A1/en not_active Abandoned
- 2004-10-14 AU AU2004285436A patent/AU2004285436C1/en not_active Ceased
- 2004-10-14 EP EP04795307A patent/EP1675651A1/en not_active Withdrawn
- 2004-10-14 WO PCT/US2004/034121 patent/WO2005042101A1/en not_active Ceased
- 2004-10-14 KR KR1020067009822A patent/KR100894465B1/ko not_active Expired - Fee Related
- 2004-10-14 NZ NZ546662A patent/NZ546662A/en unknown
-
2006
- 2006-03-27 IL IL174591A patent/IL174591A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ546662A (en) | 2009-03-31 |
| JP2007509146A (ja) | 2007-04-12 |
| EP1675651A1 (en) | 2006-07-05 |
| AU2004285436B2 (en) | 2009-01-08 |
| KR20080109101A (ko) | 2008-12-16 |
| CA2553156A1 (en) | 2005-05-12 |
| US20050113452A1 (en) | 2005-05-26 |
| WO2005042101A8 (en) | 2006-10-19 |
| MXPA06004327A (es) | 2007-01-26 |
| KR20070085032A (ko) | 2007-08-27 |
| WO2005042101A1 (en) | 2005-05-12 |
| AU2004285436C1 (en) | 2009-07-16 |
| AU2004285436A1 (en) | 2005-05-12 |
| KR100894465B1 (ko) | 2009-04-22 |
| EA200600626A1 (ru) | 2007-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL174591A0 (en) | Composition and dosage form for sustained effect of levodopa | |
| AU2003259735A8 (en) | Small-mer compositions and methods of use | |
| EP1578403A4 (en) | MODIFIED RELEASE MILNACIPRANE COMPOSITIONS | |
| IL175314A0 (en) | Administration of levodopa and carbidopa | |
| IL218357A0 (en) | Compositions and methods of using angiopoietin-like 4 protein | |
| IL164370A0 (en) | Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease | |
| AU2003220361A8 (en) | Benzamides and compositions benzamides for use as fungizide | |
| IL183986A0 (en) | Pharmaceutical compounds and compositions | |
| AU2003299441A8 (en) | Nf-hev compositions and methods of use | |
| IL166608A0 (en) | Anti-microbial compositions and methods of using same | |
| GB0404327D0 (en) | Pharmaceutical composition and method of using same | |
| HU0302441D0 (en) | Pharmaceutical compositions having antibiothic effect | |
| GB0212405D0 (en) | Composition and its therapeutic use | |
| IL178067A0 (en) | Pharmaceutical dosage forms and compositions | |
| IL174144A0 (en) | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone | |
| PT1667693E (pt) | Composições e métodos para usar corpos lamelares com fins terapêuticos | |
| GB0324523D0 (en) | Compositions and methods of treatment | |
| AU2003294684A8 (en) | Ketoprofen compositions and methods of making them | |
| IL175746A0 (en) | Oral formulations of desoxypeganine and uses thereof | |
| EP1534293A4 (en) | INFLAMMATORY COMPOSITIONS AND METHODS OF ADMINISTRATION | |
| AU2003268078A8 (en) | Levothyroxine compositions and methods | |
| GB0327050D0 (en) | Therapeutic methods compositions and uses | |
| HK1093169A (en) | Composition and dosage form for sustained effect of levodopa | |
| IL177751A0 (en) | Pharmaceutical composition of (+)-erythro-mefloquine and its use | |
| GB0309509D0 (en) | Pharmaceutical compositions and their uses |